

Index

- AB, *see* azobenzene
- AB photoisomerization 44, 52–53
- AB photoswitching 52
- adenine 94–95, 97
- AFM, *see* atomic force microscopy
- AgNPs, *see* silver nanoparticles
- amino acids 82, 89–91, 98, 219–220, 224–225, 227
- anticancer drugs 162, 170, 172, 175–176, 179, 291
- APV, *see* avipoxvirus
- aryl diazonium salts 2, 15–16, 21
- aryl film thickness 3–5, 11
- aryl films 2–6, 8–11
- atom transfer, surface-initiated 38–39
- atomic force microscopy (AFM) 3–4, 10, 14, 17–18, 39, 54, 61–62, 72, 77, 86–88, 97, 222
- atomic transfer radical polymerization (ATRP) 54, 60–61
- ATRP, *see* atomic transfer radical polymerization
- AuNPs, *see* gold nanoparticles
 - functionalised 244
 - internalised 254, 257, 259
- AuNRs, *see* gold nanorods
- avipoxvirus (APV) 88
- azobenzene (AB) 35–37, 40, 42, 44, 48–52, 54
- azobenzenes, alkyne 37–38
- biomedical applications 168, 278
- biomolecules/markers 245
- Bovine Serum Albumin (BSA) 59, 64–67, 227, 285
- 2-bromoisobutyryl bromide 37, 39, 60, 62
- BSA, *see* Bovine Serum Albumin
- BSA adsorption 65–67
- BSA molecules 66–67
- cancer 159–160, 169, 171–172, 177, 184, 188, 247, 261
- cancer cells 162, 165, 172, 177–180, 187–188, 248, 250–251, 290, 294
 - breast 173, 176
 - lung 168
- cancer chemotherapy, image-guided 175
- cancer diagnostic 160, 162, 189
- cancer theranostics 160, 162, 169, 171, 173, 175, 177–179, 181, 183, 185, 187
- carbon monoxide 248
- catalysts 110–113, 115–117, 119, 121, 125, 130, 134
- CDH, *see* cellobiose dehydrogenase
- cell biology 150
- cell membranes 83–85, 280, 291
- cell penetrating peptides (CPPs) 241–242
- cellobiose dehydrogenase (CDH) 116, 119, 124–125
- cells
 - bacterial 87

- biofuel 112, 125, 127
- blood 86, 248
- C-26 185–186
- endothelial 161, 254, 278, 284, 288–289
- fibroblast 279
- hypoxic 288
- mammalian 172
- spectro-electrochemical 121
- cellular interaction and uptake of
 - SERS nanosensors 278–279, 281, 283
- cellular SERS nanoprobe
 - 284–285, 287, 289, 291, 293
- chemometrics 88–89
- chemotherapeutic drug molecules 189
- chemotherapeutic drugs 160, 162, 174, 189
- chemotherapy 172, 177
- CPPs, *see* cell penetrating peptides
- crystal violet (CV) 115–116, 164, 261, 291, 293
- CV, *see* crystal violet
- cytochromes 85–86, 113–114, 119, 127, 129–131, 201–202, 206, 208–211
- cytosine 94–95
- DDA, *see* discrete dipole approximation
- density-functional theory (DFT) 94
- DFT, *see* density-functional theory
- di-mercaptoazobenzene (DMAB) 75, 77, 79–80
- diarylethenes 34, 52–53
- diazonium salts 2–5, 7–9, 11, 13, 15, 17–19, 21, 54
- discrete dipole approximation (DDA) 3, 6, 13, 17, 21
- DLS, *see* dynamic light scattering
- DMAB, *see* di-mercaptoazobenzene
- DNA 82, 94–95, 98, 147, 149, 247, 281
- DNA strands, single 94–96
- double strand breaks (DSBs) 97
- DOX 174, 244, 249–250, 261, 285–286
- DOX-AuNPs@gelatin 174
- DOX nanoparticles 261–262
- doxorubicin 172–173, 176–179, 285
- doxorubicin molecules 172–173
- drug delivery 2, 58, 173–175, 189, 263
- dynamic process of 162, 172–173, 177
- drug release 171, 173, 177–178, 261
- drugs, photosensitizing 170, 189
- DSBs, *see* double strand breaks
- Dynamic light scattering (DLS) 227
- E-field, *see* electromagnetic field
- E-field distribution 204–205
- EBL, *see* electron beam lithography
- EF, *see* enhancement factor
- electrocatalysis 110–111, 113, 130
- electrocatalytic reactions 111
- electrochemical sensors 110, 112
- electrochemistry 113, 115, 120
- electrodes 111–113, 115–117, 119–121, 123–126, 128, 130–131, 133–134
- electromagnetic field (E-field) 21, 147, 200–201, 205, 210, 229

- electron beam lithography (EBL)
 - 11, 15, 22, 37, 54, 59, 61, 145
- electron transfer 2, 8, 77, 111–112, 125, 130, 288
- electron transfer pathways
 - 124–125, 129
- emitters, fluorescent 142–143, 149–150
- endocytosis 236–238, 242, 257, 265, 279
- endolysosomal pathway 241, 256–257
- endosomes 237, 250, 256–258, 279, 286
 - early 237–238, 279
 - late 237–238, 279
- enhancement, local excitation
 - intensity 145–146
- enhancement factor (EF) 8, 46–47, 54, 143–145, 148–149, 183, 225, 228, 289
- enzymes 110, 112–113, 124–125, 127–128, 130, 140, 181, 238, 247–248, 293
 - single polymerase 149
- excitation 10, 19, 45, 49, 78, 141, 146, 163, 165, 168, 183, 185–186, 199–201, 206, 211
- excitation intensity 141–143

- FCS, *see* fluorescence correlation spectroscopy
- fluorescence correlation spectroscopy (FCS) 147, 227
- fluorescence emission 144, 148, 182
- fluorescence enhancement 140, 142, 144–147, 150
- fluorescence enhancement factors 143, 145
- fluorescence imaging 172, 182, 187, 233
- fluorescence signal 150, 173, 185
- fluorescence spectroscopy
 - enhancement on photonic nanoantennas 140, 142, 144, 146, 148, 150
- Förster resonance energy transfer (FRET) 150–151, 176, 220
- Fourier polar analysis (FPA) 224–225
- FPA, *see* Fourier polar analysis
- FRET, *see* Förster resonance energy transfer
- fuel cells 110–111, 134

- galvanic replacement 200–201, 204, 212
- gold nanodisks 15–16, 18, 21
- gold nanoparticles (AuNPs) 1–4, 33, 35–37, 39–42, 54, 164–165, 172–174, 234, 239, 241–243, 255–257, 278, 280–281, 284, 294–296
- gold nanorods (AuNRs) 11–14, 146, 166–167, 178–179, 239, 285, 287
- gold nanostars 174–175, 183
- gold nanostripes 4, 6, 8, 11
- gold nanostructures 66, 74, 295
- Golgi apparatus 237–238, 279
- grafting, aryl film 8, 10–13
- grafting of PNIPAM 39, 62–63
- growth factor receptors 290, 292

- hangman complexes 130–131
- HCA, *see* hierarchical clustering analysis

- HEBDT, *see* 4-(2-hydroxyethyl)-benzene diazonium tetrafluoroborate
- hemozoin crystals 86
- hierarchical clustering analysis (HCA) 224–225
- hot electron chemistry 72–73
- hot electron-induced reaction 74–75
- 4-(2-hydroxyethyl)-benzene diazonium tetrafluoroborate (HEBDT) 3–4, 61
- Raman bands 45, 75, 84, 224, 227, 229
- Raman reporter molecules 161, 163, 168, 170, 248, 290
- Raman scattering, tip-enhanced 72–73
- Raman shift 225, 292
- Raman signal 72, 78, 86, 117, 199, 206, 252, 254, 290
- Raman spectroscopy 72–73, 117, 172, 174, 176, 184, 220–221, 233
- surface-enhanced 22
- reaction time constant 26
- reactive oxidative species (ROS) 243, 246, 278, 289
- receptor-mediated endocytosis (RME) 236–237, 242, 279
- redox chemistry 128, 131
- redox reactions 115
- redox transition 115, 121, 128
- reporter-free SERS 245, 247, 253–255, 257, 259–261, 263, 265
- RME, *see* receptor-mediated endocytosis
- RNA 82, 94–95, 281
- ROS, *see* reactive oxidative species
- SAMs, *see* self-assembled monolayer
- scanning electron microscopy (SEM) 3, 16–17, 19–20, 23
- scanning probe microscopy (SPM) 72, 77
- secondary lysosome (SL) 237–238
- SEF, *see* surface-enhanced fluorescence
- self-assembled monolayer (SAMs) 26, 52
- SEM, *see* scanning electron microscopy
- sensing applications 22, 246, 248
- sensitive detection of proteins 201
- sensitivity 84–85, 87, 94–95, 117, 131, 134, 140, 150, 163, 166, 201, 221–222, 234, 248, 251–252
- SERS, *see* surface-enhanced Raman spectroscopy
- SERS-traceable drug nanocarriers 160, 162
- SERS-traceable plasmonic nanoparticles 171, 189
- silica, mesoporous 176–177, 262
- silver electrodes 76, 199, 263
- silver nanocubes 147, 204–205
- silver nanoparticles (AgNPs) 164, 168, 234–236, 263, 285, 291
- silver porous nanocubes 209, 211–212
- singlet oxygen generation 181, 183, 189
- SL, *see* secondary lysosome
- spexels 226–227
- SPM, *see* scanning probe microscopy
- surface-enhanced fluorescence (SEF) 45, 53–54
- surface-enhanced Raman scattering 22, 72, 160, 199

- surface-enhanced Raman spectroscopy (SERS) 20–22, 47–48, 72–73, 75–78, 160–161, 163, 176–177, 179, 182–185, 199–200, 233–235, 244–245, 249–253, 262–264, 285–286
- surface plasmons 72–75
- synergistic chemo-photothermal therapy 177–178
- TEM, *see* transmission electron microscopy
- TERS, *see* tip-enhanced Raman spectroscopy
- theranostic agents 162, 169–170, 178, 185, 189
- theranostic nanoparticles 162, 170, 184–185
- theranostic platforms 178–179
- theranostics 162, 175
- thiol-ene “click” chemistry 2, 23, 25, 27
- thiol-ene reaction 27–28
- thiophenol 24, 26–28, 77
- thymine 94–95
- TMV, *see* tobacco mosaic virus
- tobacco mosaic virus (TMV) 88
- toxicity 166, 234–235, 242–243, 245, 250, 278
- transmission electron microscopy (TEM) 203–204, 252, 254, 279
- tumors 160–162, 170–171, 174
- tumour cells, circulating 248–249
- UV light 22–24, 28, 43, 52
- Varicella-zoster virus (VZV) 88–89
- VZV, *see* Varicella-zoster virus
- zero-mode waveguides 149

“Following the discovery of plasmonic enhancement, an interdisciplinary community dedicated a strong effort to apply this phenomenon to biochemical detection. The success was so relevant that now we can talk about theranostics in medicine, an approach crucially based on the plasmonic local field enhancement. This compendium will be a useful reference for students and researchers who want to enter this research area and utilize the advances and extend the knowledge to future applications in this fertile field.”

Prof. Enzo Di Fabrizio

King Abdullah University of Science and Technology, Saudi Arabia

Plasmonic nanoparticles have been the subject of extensive research owing to their remarkable optical properties, known as localized surface plasmon (LSP). LSP is characterized by (i) a strong light absorption and scattering of the light depending on the geometrical parameters of nanoparticles and (ii) a strong amplification of the local field in the vicinity of nanoparticles. Quite recently, it was shown that the activation and the initiation of chemical reactions or physical processes can be facilitated using LSP excitation. Such exploitation presents two main advantages: an enhanced yield and a fine control of chemical reactions at the nanoscale. These topics have become very active and are in line with molecular plasmonics. This book explores this new field and provides a broad view on the exploitation of plasmonics in chemical and biological fields. In particular, it emphasizes that LSP excitation can be employed as a tool to promote and probe specific physical, chemical, or biological effects at the nanoscale.



Marc Lamy de la Chapelle is professor at Le Mans Université, France. His research activities concern plasmonics and surface-enhanced Raman scattering (SERS) and are focused on the fundamentals of these effects and their applications to biological issues (biomolecule detection, structural studies, biosensors, etc.), especially to the diagnosis of pathologies. He manages several research projects at national and international levels. He was also director of the CNRS National Research Network on Molecular Plasmonics and Enhanced Spectroscopies. Prof. Lamy de la Chapelle has authored more than 100 international publications (more than 5700 citations, h-index = 32) and 7 book chapters, has edited or coauthored 6 books, and holds 3 patents.



Nordin Felidj is professor at Université Paris Diderot, France, leader of the “Molecular Plasmonics” group, and vice-director of the CNRS National Research Network on Molecular Plasmonics and Enhanced Spectroscopies. His scientific research is related to plasmonics and SERS (mechanisms of the SERS effect, elaboration of hot-spot structures for single-molecule detection by SERS, optical studies of hybrid plasmonic structures, and plasmonics for chemistry). He manages several research projects at national and international levels. Prof. Felidj has authored more than 90 international publications and 6 book chapters and holds 1 patent.



PAN STANFORD PUBLISHING

www.panstanford.com

